Dr. Tanya Dorff discusses CAR T-cell research in prostate cancer

Tanya Dorff, MD, discusses findings from a phase 1 clinical trial (NCT03873805) which explored the use of chimeric antigen receptor (CAR) T-cell therapy in patients with prostate cancer. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.